학술논문
BCL2L12 protein overexpression is associated with favorable outcome in diffuse large B-cell lymphoma patients in the rituximab era.
Document Type
Article
Author
Source
Subject
*DIFFUSE large B-cell lymphomas
*BCL-2 proteins
*PROTEIN overexpression
*RITUXIMAB
*GENETIC overexpression
*CYCLOPHOSPHAMIDE
*DOXORUBICIN
*VINCRISTINE
*CANCER chemotherapy
*GENETICS
*
*
*
*
*
*
*
*
*
Language
ISSN
1042-8194
Abstract
The article discusses the overexpression of BCL2L12 protein associated with favorable outcome in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab. The study included formalin-fixed paraffin-embedded tissue biopsies from newly diagnosed DLBCL patients, and other conventional chemotherapy treatments like cyclophosphamide, doxorubicin, and vincristine. Assessments performed include immunohistochemistry, RNA isolation from cultured cells, and multivariate Cox regression.